Rapid Novor, Inc. Company Research Report
Company Overview
Name and Mission of the Company
Name: Rapid Novor, Inc.
Mission: To empower life science breakthroughs with next generation protein sequencing.
Foundation
Founded: 2015
Founders: No specific information on individual founders available.
Key People
1. Dr. Bin Ma, PhD
- Title: President and Chief Scientist
- Background: Over 20 years in bioinformatics research and technology commercialization.
2. Mingjie Xie, MSc, MBA
- Title: Chief Executive Officer
- Background: Co-founder of Rapid Novor, holds a dual MBA, and has extensive experience in biotech commercialization.
3. Qixin Liu, MSc
- Title: Chief Technology Officer
- Background: Extensive experience in developing and commercializing bioinformatics technologies.
4. Liqiang Yang, PhD
- Title: Chief Strategy Officer
- Background: 18 years of clinical development experience in oncology drugs.
5. Iain Rogers, MBA
- Title: VP Sales and Marketing
- Background: 15+ years in sales and marketing leadership.
Headquarters
Location: Unit 450, 137 Glasgow St., Kitchener, Ontario, Canada N2G 4X8
Number of Employees
Over 50 employees
Revenue
No information is available
Notable for
Rapid Novor, Inc. is known for being the world's largest privately-funded mass spectrometry proteomics facility, with extensive expertise in antibody and protein sequencing, discovery, and characterization.
Products
Protein Sequencing Service
Rapid Novor offers advanced protein sequencing services through mass spectrometry. These services are pivotal for biotech and pharmaceutical companies to unlock detailed insights into protein structure and function.
Antibody Sequencing Service
A specialized service for sequencing monoclonal and polyclonal antibodies, enabling reliable discovery and development of novel diagnostics and therapeutics.
Polyclonal Antibody Sequencing
Provides detailed sequencing information on polyclonal antibodies, facilitating deep insights into polyclonal mixtures.
Antibody Discovery
Services designed to discover novel antibodies directly from the immune response, leveraging next-generation protein sequencing to rapidly identify target-specific antibodies.
HDX-MS Epitope Mapping
High-resolution epitope mapping via Hydrogen Deuterium Exchange Mass Spectrometry (HDX-MS), allowing detailed characterization of antibody-antigen interactions.
Surface Plasmon Resonance (SPR)
SPR-based services for full kinetic analysis and rapid screening of antibody-antigen binding, essential for understanding binding kinetics and affinities.
Antibody Characterization
Broad characterization services built on advanced mass spectrometry and bioinformatics, offering detailed analyses of antibody structure, function, and interaction dynamics.
Recent Developments
New Products and Features
1. EasyM™ for Multiple Myeloma (22 May 2024)
- Development: Rapid Novor has teamed up with PMCC to evaluate EasyM™ for monitoring minimal residual disease in multiple myeloma.
2. AI-Guided Epitope Mapping Service (13 March 2024)
- Partnership: Collaborated with MAbSilico to introduce the world’s first AI-guided epitope mapping service for antibodies.
3. Functional Antibody Sequencing from Human Blood (5 June 2023)
- Innovations: Achieved a breakthrough in sequencing functional antibodies directly from human blood samples.
Certifications and Approvals
- CLIA Certification (16 March 2023)
- Announcement: Rapid Novor’s blood test for monitoring multiple myeloma is CLIA certified for clinical use in the US.
Other Developments
- Alpaca Serum Antibodies Sequencing (19 July 2022)
- Innovation: Decoding alpaca serum antibodies using de novo protein sequencing technology.
Note: This report only includes information obtained from the provided data. For items with no data available, "No information is available" has been mentioned.
